Investment
Features
FeesSafety
Academy
More
Pluang+

Viridien appoints Henning Berg as CEO and board member to lead next growth phase.

Company Fundamentals
03 Jun 2026
Na
View Source
Bullish
Viridien appoints Henning Berg as CEO and board member to lead next growth phase.

Viridien held its General Meeting on June 3, 2026, where Henning Berg was appointed as CEO and board member, succeeding Sophie Zurquiyah who remains as Chairwoman. Berg brings over 27 years of international energy sector experience and aims to drive innovation and sustainable growth at Viridien. The meeting also approved financial accounts, executive pay resolutions, and authorized share allocations. The board now includes 9 directors, with a strong representation of independent members and women, maintaining its committee structures. This leadership change marks a strategic step for Viridien's continued expansion and value creation.

More News

Constellation Brands beats earnings and revenue estimates with strong beer and spirits sales.

Constellation Brands beats earnings and revenue estimates with strong beer and spirits sales.

Constellation Brands reported earnings per share of $3.74, surpassing analyst estimates of $3.55, and revenue of $2.63 billion, exceeding the $2.54 billion forecast. The company saw a 5% increase in beer sales and a 17% rise in wine and spirits sales...

Company Fundamentals
Bullish
2 hours ago
Tilray Brands to report Q1 2027 results with expected revenue growth and ongoing losses

Tilray Brands to report Q1 2027 results with expected revenue growth and ongoing losses

Tilray Brands will announce its fiscal Q1 2027 earnings on October 8, with analysts forecasting a loss of $0.16-$0.19 per share on revenues around $265-$268 million, marking about 26% growth from last year. Investors will focus on cannabis and bevera...

Company Fundamentals
Neutral
2 hours ago
Five stocks jump 21%-53% on news of acquisitions, blockchain, AI, and federal financing.

Five stocks jump 21%-53% on news of acquisitions, blockchain, AI, and federal financing.

On October 6, 2026, five notable stocks surged between 20.9% and 52.7%, driven by various positive developments. Apimeds Pharmaceuticals rose 52.7% after its subsidiary signed a blockchain contract, while Option Care Health gained 32.7% following a $...

Market News
Bullish
2 hours ago
Five stocks drop sharply on Oct 6, led by ArriVent BioPharma after lung cancer drug trial failure.

Five stocks drop sharply on Oct 6, led by ArriVent BioPharma after lung cancer drug trial failure.

On October 6, five notable stocks saw significant declines, with losses ranging from 17.5% to 50.1%. ArriVent BioPharma's shares plunged 46.9% after its lung cancer treatment failed to meet the primary endpoint in a Phase 3 trial. Armada Acquisition ...

Market News
Bearish
2 hours ago
Evercore raises Marvell's price target to $433 on strong AI and data center growth forecasts.

Evercore raises Marvell's price target to $433 on strong AI and data center growth forecasts.

Evercore ISI raised its price target for Marvell Technology to $433 from $275, maintaining an Outperform rating. This follows Marvell's optimistic revenue projections, expecting $20 billion by fiscal 2028 and $70-$90 billion by fiscal 2031, driven by...

Analyst Insights
Bullish
3 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App